Agoracom Blog Home

Posts Tagged ‘CBD’

Marijuana Company of America Has Engaged Auditing Firm to Prepare for Move to Fully Reporting Public Company $MCOA.us

Posted by AGORACOM-JC at 10:00 AM on Tuesday, December 27th, 2016

15233 mcoa

  • Engaged L&L CPAs, PA as its independent audit firm to complete a two-year audit of the Company’s financial statements as part of the process of preparing to become a fully reporting public company with the intent of uplisting to a higher reporting exchange
  • Newly engaged auditors are working together with the Company’s legal counsel to complete the necessary procedures to file a registration statement with the Securities and Exchange Commission

BONSALL, CA–(Dec 27, 2016) – MARIJUANA COMPANY OF AMERICA INC., (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp marketing, consulting and distribution company, has engaged L&L CPAs, PA as its independent audit firm to complete a two-year audit of the Company’s financial statements as part of the process of preparing to become a fully reporting public company with the intent of uplisting to a higher reporting exchange.

The newly engaged auditors are working together with the Company’s legal counsel to complete the necessary procedures to file a registration statement with the Securities and Exchange Commission. When completed and filed with the Commission, this will represent a significant step toward our efforts to enhance long-term shareholder value, while attracting a broader and more diverse shareholder base.

“Our goal is to be a fully transparent reporting public company,” said the Company’s CEO, Donald Steinberg. “As we grow and take these major steps, we want our shareholders to be well-informed about our plans and our progress. By becoming a fully-reporting, transparent public company, we may be better positioned to enhance stock liquidity and attract institutional investors, which will fundamentally enhance the value of our Company.”

Once the audit is completed over the next several months, the Company will have a better idea which stock exchange is most appropriate for the Company. “Our goal is to be fully reporting on the most reputable exchange we qualify for, so our shareholders have all the information they need to follow our progress in detail,” said Mr. Steinberg.

L&L CPAs, PA is registered with the PCAOB and is experienced in conducting audits of public companies in the cannabis industry. Completing this audit will help ensure the accuracy and completeness of the Company’s financial information, and also help to identify and strengthen internal controls over financial reporting.

About Marijuana Company of America Inc.

Marijuana Company of America (“MCOA”) is a publicly traded company headquartered in Southern California. MCOA will distribute marijuana and products related to marijuana as well as CBD and hemp, using a variety of marketing approaches to distribute on a global basis.

SAFE HARBOR STATEMENT:

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
Harmoneous.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Investor Relations
888-777-4362
ir@mcoa.club

More than $1 billion of marijuana sold in Colorado in 2016 $TBP.ca $MCOA.us

Posted by AGORACOM-JC at 4:23 PM on Tuesday, December 13th, 2016
Image result for cnn
  • Last year, the marijuana industry created 18,000 full-time jobs and generated $2.39 billion in economic activity in the state.
  • Recreational and medical cannabis shops have sold more than $1 billion of marijuana and related products so far in 2016, already surpassing last year’s total of $996,184,788

(CNN) It’s always 4/20 somewhere — at least in Colorado. The state’s marijuana shops have reached a massive new milestone: $1 billion in legal, regulated sales in the first 10 months of 2016.
Voters legalized marijuana in Colorado back in 2012, but the dispensaries didn’t open until 2014Last year, the marijuana industry created 18,000 full-time jobs and generated $2.39 billion in economic activity in the state.

And the boom is still growing. According to new data from the state’s Department of Revenue, recreational and medical cannabis shops have sold more than $1 billion of marijuana and related products so far in 2016, already surpassing last year’s total of $996,184,788.

Attorney Christian Sederberg, partner at Vicente Sederberg, played an integral part in Colorado’s Amendment 64, which legalized marijuana in the state. He is estimating that sales of pot will reach $1.3 billion by the end of this year, which could have a total economic impact of over $3 billion.
Designer marijuana boosts THC potency
Designer marijuana boosts THC potency 02:24
“This milestone continues to show that the cannabis industry in Colorado is an engine of growth for the economy, a job creator, and one of the biggest industries in the state,” Sederberg told CNN. “People were consuming cannabis before, but now they are buying it from tax-regulated businesses that are benefiting the economy. This has replaced an underground, illegal market.”
Sederberg says that marijuana has become one of the largest industries in Colorado, and certainly the fastest growing.
“From 2015 to 2016, there has been a 53% increase in retail sales and a 9% increase in medical sales,” he said. “Medical sales are growing at a much slower rate, but recreational sales will continue to grow in the double digits.”

All-time high

Marijuana sales in Colorado hit an all-time high in September 2016, generating $127.8 million, according to The Cannabist, a Colorado-based news site covering the industry. But October’s numbers are still sizable: Shops sold nearly $82.8 million of recreational cannabis and $35 million of medical marijuana.
Colorado has three different taxes on recreational marijuana — a standard 2.9% sales tax, a special 10% sales tax, and a 15% excise tax on wholesale transfers, which go towards schools. The state collected just over $6 million from the excise tax, bringing the yearly total to $49.7 million, The Cannabist tallied.
Of that, the first $40 million will go towards school construction projects, and any additional tax revenue from the excise tax will go directly to the state’s public school fund.
In this past election, California, Massachusetts, Nevada, and Maine all approved legal sales of recreational marijuana. Medical marijuana is now legal in more than half of US states. In total, marijuana sales could expand the national market to $21 billion by 2020. That is up from $5.7 billion last year and an expected $7.9 billion this year.
But in the eyes of the federal government, marijuana is still an illegal substance. The Drug Enforcement Administration classifies marijuana as a Schedule 1 drug, the same as heroin, LSD, and ecstasy.
Source: http://edition.cnn.com/2016/12/13/health/colorado-marijuana-sales-trnd/

Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001 $TBP.ca

Posted by AGORACOM-JC at 9:04 AM on Wednesday, November 23rd, 2016

Tbp large

  • Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit
  • FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

OTTAWA, ONTARIO–(Nov. 23, 2016) - PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF), is a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that the development of its smoked marijuana prescription drug is on schedule.

The Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration (“FDA“) had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit. The FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research (“CDER“) as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

The Company previously announced that it received a pre-IND (Investigational New Drug) acknowledgement and meeting request granted letter from the US FDA. This week, the company is submitting the information package required by FDA for the Type B pre-IND meeting in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research. According to Dr. G. Chamberland, Chief Science Officer, “As per FDA policies, the pre-IND information package is submitted to obtain guidance from FDA on the product development and marketing requirements for the smoked marijuana prescription drug combination product”. Dr. Chamberland further commented that this regulatory filing is part of PPP’s dedication to the commercialization of marijuana as a prescription controlled drug and the corporation’s plan to seek reimbursement by insurers for patients.

The Company has been working with Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects. PPP is using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry. Later this week the project team will be submitting the Phase I clinical protocol, and related documents, to the Institutional Review Board for review. If approved, Algorithme Pharma will subsequently submit the Clinical Trial Application to the Therapeutic Products Directorate of Health Canada for approval. In parallel, Algorithme Pharma will submit an application for exemption under section 56 of the Controlled Drugs and Substances Act for its planned research on healthy subjects.

The Company stated that, subsequent to a request for classification to the Medical Devices Bureau, Health Canada, the PPP001-titanium pipe that will be used in the clinical trial is a Class I medical device. Dr. Chamberland commented: “As a Class I medical device, the PPP001-titanium pipe does not require approval for use in the clinical trial”.

About PPP001-kit product

PPP001-kit product will be sold as two separate products packaged together in a single package and is comprised of the drug PPP001 and the device PPP001-titanium pipe. The drug component and device component will be linked together by the labelling of each component.

The product PPP001-kit, once approved, could be sold in pharmacies containing the prescription controlled drug PPP001, in a blister pack, and the PPP-titanium pipe device that will be used to generate the smoke to deliver the active ingredients by inhalation.

PPP001 drug pellet blisters and a fully assembled PPP-titanium pipe for combustion and inhalation of the generated smoke are required for therapy with PPP001 and are provided in the PPP001-kit.

Each blister of PPP001 drug pellet contains marijuana with a standardized amount of delta-9-tetrahydrocannibinol and cannibidiol. A single PPP001 drug pellet is pushed out of the blister by the patient and inserted into the PPP-titanium pipe.

In Other News:

The Company has received $227,738 in exercised warrants for November 2016.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Ryan Brown – VP Business Development and Communications
Andre Audet – Executive Chairman
Dr. Guy Chamberland – Chief Scientific Officer
(613) 421-8402

Marijuana Company of America Transitions From the Development Stage to a Revenue Generating Company $MCOA.us

Posted by AGORACOM-JC at 11:10 AM on Thursday, November 17th, 2016

15233_mcoa

  • MCOA has now commenced generating revenue and started to ship orders for its hempSMART Brain product
  • Donald Steinberg, the Company’s CEO, remarked: “Reporting revenue results to our current and prospective shareholders is an important step as the company continues to expand its footprint across America. Now that we have laid the groundwork for our affiliate program in the U.S., MCOA’s goal is to utilize its global contacts and networks to begin to expand the hempSMART brand in other countries. In the past, I have developed one of the largest affiliate marketing programs in the world, with offices in over 50 countries and an affiliate base of over 100,000 members. I will leverage that experience as we expand the hempSMART brand.”

BONSALL, CA–(Marketwired – Nov 17, 2016) –  MARIJUANA COMPANY OF AMERICA INC., (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp development and distribution company, is pleased to announce that after many months of research and product development and business planning, MCOA has now commenced generating revenue and started to ship orders for its hempSMART Brain product.

Donald Steinberg, the Company’s CEO, remarked: “Reporting revenue results to our current and prospective shareholders is an important step as the company continues to expand its footprint across America. Now that we have laid the groundwork for our affiliate program in the U.S., MCOA’s goal is to utilize its global contacts and networks to begin to expand the hempSMART brand in other countries. In the past, I have developed one of the largest affiliate marketing programs in the world, with offices in over 50 countries and an affiliate base of over 100,000 members. I will leverage that experience as we expand the hempSMART brand.”

Tim Altvater, the Company’s marketing director, commented, “The hempSMART product roll-out is a marketer’s dream come true – especially for those of us in the direct sales industry. Now we can focus on the growth of our affiliate network as people begin to use and share their experiences with hempSMART Brain and the benefits of the hempSMART compensation and rewards program. The ability for entrepreneurs to represent the highest quality products, backed by science, to consumers that are in need and seeking them is the driver for our industry’s continued growth and appeal. We’re poised to see unprecedented growth as we finish 2016 strong!”

The Company’s inaugural product, hempSMART Brain, is formulated with CBD or Cannabidiol as the core ingredient combined with high quality branded ingredients to compliment the CBD to support brain health. hempSMART Brain is formulated to meet the growing demand for neutraceutical products that assist in brain function. This is a first-of-its-kind product with a synergistic blend of natural brain support ingredients, blended with water soluble CBD to provide optimal bioavailability for brain support and protection.

Investors are invited to visit the MCOA IR Hub on Agoracom to post questions and receive answers, or review questions and answers already posted by fellow investors. In addition, the MCOA IR HUB provides a monitored forum for investors and prospective shareholders to communicate within a clean, professional environment. Investors can also visit Uptick Newswire’s MCOA Investor Central to learn more about the Company.

About Marijuana Company of America Inc.

Marijuana Company of America (“MCOA”) is a publicly traded company headquartered in Southern California. MCOA will distribute marijuana and products related to marijuana as well as CBD and hemp, using a variety of marketing approaches to distribute on a global basis.

About hempSMART

The hempSMART brand represents MCOA’s non-THC, hemp derived, product line. All hempSMART products are formulated with a cannabinoid base that is derived from hemp and has less than a .3% THC content.

About Club Harmoneous

Club Harmoneous (The Club) delivers all of the benefits of cannabis to its members harmoneously. The Club provides a wide range of cannabis products to its members, medicinal, adult use or healthy foods, body care and cosmetics. The Club products are top-quality and offered to members at competitive prices with the convenience of home delivery.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Marijuana Company of America, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

Marijuana Company of America Inc. will provide management services that assist legal businesses to cultivate, sell, and distribute hemp and marijuana based products within the legal guidelines of individual states and international markets. hempSMART products are derived from Hemp and contain than a .3% THC content.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
Harmoneous.com
Agoracom.com/ir/MarijuanaCompanyofAmerica
UptickNewswire.com/Investor-Central-MCOA
Marijuana Company of America Inc.
Investor Relations
888-777-4362
ir@mcoa.club

Tetra Bio-Pharma Achieves DTC Eligibility in the United States $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, November 16th, 2016

Tbp_large

  • Effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market
  • Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”.

OTTAWA, ONTARIO–(Nov. 16, 2016) - Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF) is pleased to announce that effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market.

Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors.

The Company’s common shares are listed for trading on the OTCPINK, a U.S. based securities trading system, under the symbol “GRPOF”. Tetra Bio-Pharma shares will continue to be traded on the Canadian Stock Exchange under its existing symbol “TBP”.

André Rancourt, Chief Executive Officer, commented, “We’re pleased to announce that our shares have become DTC eligible on the U.S. market and excited to bring our Company to the attention of the investment community in the U.S. We believe that GRPOF offers investors a unique opportunity to invest in a bio pharmaceutical cannabis company before entering clinical trials later this year.

In other company news

Website:

The Company is proud to announce that its website located at www.tetrabiopharma.com is now live. We encourage investors to sign up for news releases and notifications as more information is added to the website.

Industry Participation:

Dr. Guy Chamberland, Chief Scientific Officer and regulatory affairs, and Ryan Brown, co-founder and VP of Business Development, will be presenting at the World of Cannabis business summit in Las Vegas on November 16th 2016. Dr. Chamberland will be presenting as part of “the science of medical cannabis” program while Ryan Brown will be presenting at the “emerging brands investor pitch seminar” more info can be found at www.worldofcannabissummit.com.

Investor Relations:

The Company would like to inform investors that it has engaged Alpha Deal Group LLC, a New York based buy side analyst firm, to perform investor analysis for presentation to its investment network.

As released on November 9, 2016, via CFN (Cannabis Financial Network), the Company has engaged Cannabis Financial Network to increase its visibility in the United States retail investment market.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
Phone: (613) 421-8402

Ryan Brown
Co-founder and Director of Communications
Phone: (613) 421-8402

Andre Audet
Executive Chairman
Phone: (613) 421-8402

hempSMART.com is now live, products can be purchased, check it out! $MCOA.us

Posted by AGORACOM-JC at 6:24 PM on Monday, November 7th, 2016

hempSMART.com is now live, products can be purchased!

  • Formulated to promote brain health
  • Combines enhanced memory/cognitive function benefits with the additional benefits offered by CBD

Watch Our Recent Video

TRADE DATA!!! $MCOA.us +278% in Just 6 Trading Days

Posted by AGORACOM-JC at 4:53 PM on Thursday, November 3rd, 2016

15233_mcoa

MCOA: OTC

Marijuana Could Be The Big Winner On November 8th

  • Pot on the ballot in nine states, the big winner in next Tuesday’s election could be America’s legal cannabis industry.
  • By 2020, legal market sales are expected to surpass $22 billion.
  • For states struggling with budget shortfalls, that extra revenue would be clearly welcome.

MCOA Hub on AGORACOM / Corporate Profile / Watch Video

Marijuana Could Be The Big Winner On November 8th $MCOA.us

Posted by AGORACOM-JC at 12:33 PM on Thursday, November 3rd, 2016

  • Pot on the ballot in nine states, the big winner in next Tuesday’s election could be America’s legal cannabis industry.
  • By 2020, legal market sales are expected to surpass $22 billion.
  • For states struggling with budget shortfalls, that extra revenue would be clearly welcome.

MCOA Hub on AGORACOM / Corporate Profile / Watch Video

Tetra Bio-Pharma Announces Acquisition of Intellectual Property for the Development of Natural Health Products Through Its Agro-Tek Subsidiary $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, October 26th, 2016

Tbp_large

  • Announced that it has acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa
  • Recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content

OTTAWA, ONTARIO–(Oct. 26, 2016) - Tetra Bio-Pharma Inc. (“Tetra Bio” or the “Company“) (CSE:TBP)(CSE:TBP.CN), through its subsidiary, Agro-Tek Inc. (“AGTK“), is pleased to announce that it has acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa.

The recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content. According to the United States Food and Drug Administration (“FDA“), “FDA is not aware of any evidence that would call into question its current conclusion that cannabidiol products are excluded from the dietary supplement definition under section 201(f)(3)(B)(ii) of the Federal Food, Drug, & Cosmetics Act.”

Mr. André Rancourt, the Company’s CEO commented, “CBD or THC containing dietary supplements are currently not allowed on the USA market. However, the goal of the McGill University partnership is the development of extracts of the plant Cannabis sativa, including THC and CBD-free for the development of dietary supplements.” AGTK intends on manufacturing and commercializing supplements, food-type products and, natural health products that are compliant with Canadian and USA federal regulations. Mr. Rancourt added, “This commercial strategy involves the expertise of two of the Company’s subsidiaries, AGTK and MMP, and is in line with the Company’s vision to make AGTK and MMP leaders in the development of Cannabis sativa, derived products for the consumer market, and for the commercialization of natural supplements derived from Cannabis sativa.”

The assets acquired include proprietary formulations that have obtained marketing approval from Health Canada. The line consists of:

1. Glucose Aid; NPN 80058089

2. Kava Kava; NPN 80061986

3. Stress Ado; NPN 80065911

4. Toux Ado (Cough Ado); NPN 80065923

5. Toux enfant (Cough Children); NPN 80065928

6. Water Relax; NPN 80065948 (beverage supplement)

7. Water Cough; NPN 80066086 (beverage supplement)

8. Sleep Pro; NPN 80066679

9. Instant Relief; NPN 80066682 (topical gel for local pain relief).

The acquisition of these formulations and their proprietary ingredients will provide PhytoPain Pharma Inc. with an inventory of compounds and elements that will be used as secondary ingredients or catalysts in the formulation of our pharmaceutical grade products.

In consideration for the acquisition of the assets, the Company has issued 1,800,000 common shares to arms’ length individuals. The shares issued will be subject to a four-month hold period.

According to Mr. Rancourt, these products will allow AGTK to begin generating revenues. This is the first set of products for AGTK’s portfolio. The company will be seeking to acquire additional product lines for distribution in North America. AGTK is engaged in negotiations to acquire national distributors to expand brand identity and facilitate distribution across North America

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer

Ryan Brown
VP Business Development and Communications

Andre Audet
Executive Chairman
(613) 421-8402
Investors@tetrabiopharma.com

Marijuana Company of America Q4 2016 Outlook and Update $MCOA.us

Posted by AGORACOM-JC at 8:46 AM on Tuesday, October 18th, 2016

15233_mcoa

 

  • hempSMART Brain product release imminent
  • Offers brain support and protection
  • Product is first-of-its-kind
  • Fulfillment center prepared to manage distribution of orders
  • Members signing up for PreLaunch

BONSALL, CA–(Marketwired – Oct 18, 2016) –

MARIJUANA COMPANY OF AMERICA INC., (“MCOA” or the “Company”) (OTC PINK:MCOA), an innovative cannabis and hemp marketing and distribution company, is providing this update to keep our shareholders and prospective investors informed.

Our first product, hempSMART BRAIN, formulated with CBD or Cannabidiol as the core ingredient combined with high quality, clinically proven, branded ingredients to compliment the CBD to support brain health. There are new articles published daily regarding the benefits of CBD, hempSMART BRAIN was formulated to meet the growing demand for cannabinoid based neutraceutical products that assist in brain function.

The hempSMART Brain product is scheduled for release by the end of October. It was expected to ship by the second week of October, but delays in receiving key ingredients from suppliers has pushed back the ship date by approximately two weeks. Our fulfillment center is ready to manage distribution of orders and they are working very closely with hempSMART’s manufacturer, which will result in significant efficiencies of scale.

hempSMART Brain is a first-of-its-kind product. The synergistic blend of clinically verified natural brain support ingredients, blended with water soluble CBD, enables crossing of the blood-brain barrier to provide optimal brain support and protection.

hempSMART Brain was developed to address the increase in neurologic and neurodegenerative challenges that have prompted a surge in scientific research on prevention and/or reversal of brain and nervous system pathology. A variety of natural products have been shown, in clinical trials, to improve neurological and cognitive function and there has been a surge of products being marketed to improve brain function.

Marketing leaders are currently preparing for the Brain product roll-out. The hempSMART prelaunch website: hempSMART.com is now active and accessible to the Company’s members.

According to the Direct Selling Association, in 2015 over 20 million people in the U.S. were involved in direct selling, with total sales of $36.1 billion. More than 74 percent of the American public has purchased goods or services through direct selling. Worldwide sales are also strong with more than $154 billion in sales. This marketing and distribution method is incredibly effective at creating solid sales and loyal members, as well as brand awareness in the marketplace because the sales “force” are people that passionately believe in the company, product and the difference it can make in people’s lives. The energy they can invest into the education of potential customers is far more than any other sales model.

Another key driver in the affiliate marketing industry is compensation or commission that is based on performance. Affiliate leaders earn rewards and compensation for developing training systems for their personal sales “teams” within hempSMART. Based on this win-win business model, companies can grow rapidly due to the success of the customer, the affiliate and the entire direct sales process.

Over the years, thousands of affiliate marketing teams have been established to promote new products for launch. Our affiliate marketing leaders are well established, long-term professionals. They are testing the system as well as preparing their marketing organizations for the Brain product launch. The Company has a robust affiliate marketing program that is integrated into the hempSMART.com full website which was designed and developed by ApogeeINVENT. This user-friendly platform will help our affiliates track their commissions and provide resources, and helpful information for marketing the Company’s products.

“We have received significant interest in this product and we are looking forward to updating the financial markets and our shareholders as the product release takes place,” said CEO, Donald Steinberg.

The Club Harmoneous pilot program has been extended due to regulatory challenges under the current non-profit regulatory model in California. The Company will continue to work through these challenges to develop a unique operating model that can operate under the current regulatory framework as well as the upcoming licensing and regulatory structure proposed by the Medical Marijuana Regulation and Safety Act (MMRSA). The Company is also prepared for the passing of Prop 64 in November for the adult use of marijuana in California. The Company continues to work closely with Green Dot Collective in Los Angeles County to overcome some of the regulatory challenges and changes in California. Upon satisfactory completion of the Southern California pilot program, the Company will begin expansion to Northern California and other legal adult use and medical marijuana states.

Investors are invited to visit the MCOA IR Hub on Agoracom to post questions and receive answers, or review questions and answers already posted by fellow investors. In addition, the MCOA IR HUB provides a monitored forum for investors and prospective shareholders to communicate within a clean, professional environment.
On behalf of the Board of Directors,

“Donald Steinberg”
Donald Steinberg
President & CEO
888-777-4362
MarijuanaCompanyofAmerica.com

About Marijuana Company of America, Inc.,
Marijuana Company of America (“MCOA”) is a publicly traded company headquartered in Southern California. MCOA will distribute marijuana and products related to marijuana as well as CBD and hemp, using a variety of marketing approaches to distribute on a global basis.

About hempSMART
The hempSMART brand represents MCOA’s non-THC, hemp derived, product line. All hempSMART products are formulated with a cannabinoid base that is derived from hemp and has less than a .3% THC content.

About Club Harmoneous
Club Harmoneous (The Club) delivers all of the benefits of cannabis to its members harmoneously. The Club provides a wide range of cannabis products to its members, medicinal, adult use or healthy foods, body care and cosmetics. The Club products are top-quality and offered to members at competitive prices with the convenience of home delivery.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Marijuana Company of America, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
Marijuana Company of America Inc. will provide management services that assist legal businesses to cultivate, sell, and distribute hemp and marijuana based products within the legal guidelines of individual states and international markets. hempSMART products are derived from Hemp and contain than a .3% THC content.
For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
Harmoneous.com
agoracom.com/ir/MarijuanaCompanyofAmerica

CONTACT INFORMATION

  • Contact InformationDonald Steinberg
    President & CEO
    888-777-4362
    MarijuanaCompanyofAmerica.com